Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biofrontera (BFRI) EBIT Margin: 2020-2025

Historic EBIT Margin for Biofrontera (BFRI) over the last 5 years, with Sep 2025 value amounting to -89.84%.

  • Biofrontera's EBIT Margin fell 3480.00% to -89.84% in Q3 2025 from the same period last year, while for Sep 2025 it was -47.40%, marking a year-over-year increase of 736.00%. This contributed to the annual value of -46.11% for FY2024, which is 2044.00% up from last year.
  • Per Biofrontera's latest filing, its EBIT Margin stood at -89.84% for Q3 2025, which was down 59.73% from -56.25% recorded in Q2 2025.
  • Biofrontera's 5-year EBIT Margin high stood at -13.63% for Q4 2024, and its period low was -371.60% during Q3 2021.
  • Its 3-year average for EBIT Margin is -63.78%, with a median of -56.25% in 2025.
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by 29,952bps in 2021, then soared by 28,740bps in 2022.
  • Quarterly analysis of 5 years shows Biofrontera's EBIT Margin stood at -20.51% in 2021, then plummeted by 3,451bps to -55.02% in 2022, then skyrocketed by 1,854bps to -36.48% in 2023, then soared by 2,284bps to -13.63% in 2024, then plummeted by 3,480bps to -89.84% in 2025.
  • Its EBIT Margin was -89.84% in Q3 2025, compared to -56.25% in Q2 2025 and -52.95% in Q1 2025.